Literature DB >> 15846579

Management of anemia associated with myelodysplastic syndrome.

E Hellström-Lindberg1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15846579     DOI： 10.1053/j.seminhematol.2005.01.002

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


× No keyword cloud information.
  9 in total

1.  Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes.

Authors:  Hussam Ghoti; Eitan Fibach; Drorit Merkel; Galit Perez-Avraham; Sigal Grisariu; Eliezer A Rachmilewitz
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

2.  Geographical variations in current clinical practice on transfusions and iron chelation therapy across various transfusion-dependent anaemias.

Authors:  Vip Viprakasit; Norbert Gattermann; Jong Wook Lee; John B Porter; Ali T Taher; Dany Habr; Nicolas Martin; Gabor Domokos; Maria Domenica Cappellini
Journal:  Blood Transfus       Date:  2012-07-12       Impact factor: 3.443

Review 3.  Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.

Authors:  Niraj Shenoy; Nishanth Vallumsetla; Eliezer Rachmilewitz; Amit Verma; Yelena Ginzburg
Journal:  Blood       Date:  2014-06-12       Impact factor: 22.113

Review 4.  Oxidative Stress in β-Thalassemia.

Authors:  Eitan Fibach; Mutaz Dana
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

5.  Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange.

Authors:  Norbert Gattermann; Andrea Jarisch; Rudolf Schlag; Klaus Blumenstengel; Mariele Goebeler; Matthias Groschek; Christoph Losem; Maria Procaccianti; Alexia Junkes; Oliver Leismann; Ulrich Germing
Journal:  Eur J Haematol       Date:  2011-11-24       Impact factor: 2.997

6.  A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS.

Authors:  Aristoteles Giagounidis; Susanna Leto di Priolo; Susanne Ille; Pierre Fenaux
Journal:  Ann Hematol       Date:  2011-02-16       Impact factor: 3.673

7.  Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients.

Authors:  Hana Votavova; Zuzana Urbanova; David Kundrat; Michaela Dostalova Merkerova; Martin Vostry; Monika Hruba; Jaroslav Cermak; Monika Belickova
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-07

8.  Red cell alloimmunization is associated with development of autoantibodies and increased red cell transfusion requirements in myelodysplastic syndrome.

Authors:  Deepak Singhal; Monika M Kutyna; Rakchha Chhetri; Li Yan A Wee; Sophia Hague; Lakshmi Nath; Shriram V Nath; Romi Sinha; Nicholas Wickham; Ian D Lewis; David M Ross; Peter G Bardy; Luen Bik To; John Reynolds; Erica M Wood; David J Roxby; Devendra K Hiwase
Journal:  Haematologica       Date:  2017-10-05       Impact factor: 9.941

Review 9.  Pathophysiology and treatment of patients with beta-thalassemia - an update.

Authors:  Eitan Fibach; Eliezer A Rachmilewitz
Journal:  F1000Res       Date:  2017-12-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.